Consistent with our results in Rag1−/− mice, we observed significantly slower tumor growth (P < 0.05) in humanized tumor-bearing mice treated with anti-hPVRIG mAb compared to those treated with control antibody (Fig. 7i), indicating that PVRIG blockade in humanized mice could benefit directly via NK cells. The gene discussed is RAG1; the disease is neoplasm.